相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nanoparticle Delivered VEGF-A siRNA Enhances Photodynamic Therapy for Head and Neck Cancer Treatment
Rumwald Leo G. Lecaros et al.
MOLECULAR THERAPY (2016)
Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy
Megan S. Keiser et al.
BRAIN (2015)
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients
Edward J. Wild et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease
Kristina Becanovic et al.
NATURE NEUROSCIENCE (2015)
Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression
Amber L. Southwell et al.
SCIENTIFIC REPORTS (2015)
Lentiviral vectors as tools to understand central nervous system biology in mammalian model organisms
Louise C. Parr-Brownlie et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2015)
Artificial miRNAs Targeting Mutant Huntingtin Show Preferential Silencing In Vitro and In Vivo
Alex Mas Monteys et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Onset Time and Durability of Huntingtin Suppression in Rhesus Putamen After Direct Infusion of Antihuntingtin siRNA
Richard Grondin et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1
Sanjay K. Pandey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease
Lisa M. Stanek et al.
HUMAN GENE THERAPY (2014)
Broad Therapeutic Benefit After RNAi Expression Vector Delivery to Deep Cerebellar Nuclei: Implications for Spinocerebellar Ataxia Type 1 Therapy
Megan S. Keiser et al.
MOLECULAR THERAPY (2014)
In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides
Amber L. Southwell et al.
MOLECULAR THERAPY (2014)
Nonallele Specific Silencing of Ataxin-7 Improves Disease Phenotypes in a Mouse Model of SCA7
Pavitra S. Ramachandran et al.
MOLECULAR THERAPY (2014)
Intrajugular Vein Delivery of AAV9-RNAi Prevents Neuropathological Changes and Weight Loss in Huntington's Disease Mice
Brett D. Dufour et al.
MOLECULAR THERAPY (2014)
Regulation of microRNA biogenesis
Minju Ha et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
RNA Interference-Based Therapy for Spinocerebellar Ataxia Type 7 Retinal Degeneration
Pavitra S. Ramachandran et al.
PLOS ONE (2014)
Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
Niels H. Skotte et al.
PLOS ONE (2014)
Neuroanatomical correlates of cognitive functioning in prodromal Huntington disease
Deborah L. Harrington et al.
BRAIN AND BEHAVIOR (2014)
Biology of adeno-associated viral vectors in the central nervous system
Giridhar Murlidharan et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2014)
Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl-Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates
Frank Rigo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study
Eric A. Epping et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
Cognitive Reserve and Brain Reserve in Prodromal Huntington's Disease
Aaron Bonner-Jackson et al.
JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study (vol 12, pg 435, 2013)
T. M. Miller et al.
LANCET NEUROLOGY (2013)
Toward RNAi Therapy for the Polyglutamine Disease Machado-Joseph Disease
Maria do Carmo Costa et al.
MOLECULAR THERAPY (2013)
Silencing Mutant ATXN3 Expression Resolves Molecular Phenotypes in SCA3 Transgenic Mice
Edgardo Rodriguez-Lebron et al.
MOLECULAR THERAPY (2013)
RNAi or overexpression: Alternative therapies for Spinocerebellar Ataxia Type 1
Megan S. Keiser et al.
NEUROBIOLOGY OF DISEASE (2013)
Recent Advances in RNA Interference Therapeutics for CNS Diseases
Pavitra S. Ramachandran et al.
NEUROTHERAPEUTICS (2013)
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
Michael E. Ostergaard et al.
NUCLEIC ACIDS RESEARCH (2013)
Silencing Mutant Ataxin-3 Rescues Motor Deficits and Neuropathology in Machado-Joseph Disease Transgenic Mice
Clevio Nobrega et al.
PLOS ONE (2013)
Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7
Udo Rueb et al.
PROGRESS IN NEUROBIOLOGY (2013)
Pre-existing Anti-Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Vedell Louis Jeune et al.
HUMAN GENE THERAPY METHODS (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
Timothy M. Miller et al.
LANCET NEUROLOGY (2013)
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum
Richard Grondin et al.
BRAIN (2012)
Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression
Dongbo Yu et al.
CELL (2012)
Single-Stranded siRNAs Activate RNAi in Animals
Walt F. Lima et al.
CELL (2012)
Widespread suppression of huntingtin with convection-enhanced delivery of siRNA
David K. Stiles et al.
EXPERIMENTAL NEUROLOGY (2012)
The advent of AAV9 expands applications for brain and spinal cord gene delivery
Robert D. Dayton et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Cognitive domains that predict time to diagnosis in prodromal Huntington disease
Deborah Lynn Harrington et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Neutralizing Antibodies Against AAV Serotypes 1, 2, 6, and 9 in Sera of Commonly Used Animal Models
Kleopatra Rapti et al.
MOLECULAR THERAPY (2012)
Huntingtin Holiday: Progress toward an Antisense Therapy for Huntington's Disease
Xiao-Hong Lu et al.
NEURON (2012)
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Holly B. Kordasiewicz et al.
NEURON (2012)
Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice
Mireia Garriga-Canut et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Jean Bennett et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Mutant Huntingtin Causes Metabolic Imbalance by Disruption of Hypothalamic Neurocircuits
Sofia Hult et al.
CELL METABOLISM (2011)
Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2011)
Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene/Allele-Specific Silencing of Mutant Huntingtin
Jeffrey B. Carroll et al.
MOLECULAR THERAPY (2011)
Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease
Jodi L. McBride et al.
MOLECULAR THERAPY (2011)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG Repeat
Keith T. Gagnon et al.
BIOCHEMISTRY (2010)
Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors
Sylvie Boutin et al.
HUMAN GENE THERAPY (2010)
Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
Sandro Alves et al.
HUMAN MOLECULAR GENETICS (2010)
Sustained Effects of Nonallele-Specific Huntingtin Silencing
Valerie Drouet et al.
ANNALS OF NEUROLOGY (2009)
Allele-Selective Inhibition of Mutant Huntingtin by Peptide Nucleic Acid-Peptide Conjugates, Locked Nucleic Acid, and Small Interfering RNA
Jiaxin Hu et al.
OLIGONUCLEOTIDE THERAPEUTICS (2009)
Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl]pyrrolocytosine
Jiaxin Hua et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease Patients
Edith L. Pfister et al.
CURRENT BIOLOGY (2009)
A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference
Maria Stella Lombardi et al.
EXPERIMENTAL NEUROLOGY (2009)
Ribonuclease H: the enzymes in eukaryotes
Susana M. Cerritelli et al.
FEBS JOURNAL (2009)
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2009)
Artificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivo
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
Detection of Intact rAAV Particles up to 6 Years After Successful Gene Transfer in the Retina of Dogs and Primates
Knut Stieger et al.
MOLECULAR THERAPY (2009)
Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs
Jiaxin Hu et al.
NATURE BIOTECHNOLOGY (2009)
A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy
Natalia N. Singh et al.
RNA BIOLOGY (2009)
Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in Transgenic mice
Yimin Hua et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration
Gwenn A. Garden et al.
CEREBELLUM (2008)
Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts
P. H. J. van Bilsen et al.
HUMAN GENE THERAPY (2008)
Delivery vehicles for small interfering RNA in vivo
Antonin R. De Fougerolles
HUMAN GENE THERAPY (2008)
AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease
Nicholas R. Franich et al.
MOLECULAR THERAPY (2008)
Allele-Specific RNA Silencing of Mutant Ataxin-3 Mediates Neuroprotection in a Rat Model of Machado-Joseph Disease
Sandro Alves et al.
PLOS ONE (2008)
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi
Jodi L. McBride et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits
M. DiFiglia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
Eric E. Swayze et al.
NUCLEIC ACIDS RESEARCH (2007)
Antisense oligonucleotide therapy for neurodegenerative disease
Richard A. Smith et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Adeno-associated virus serotypes: Vector toolkit for human gene therapy
Zhijian Wu et al.
MOLECULAR THERAPY (2006)
Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA
YL Wang et al.
NEUROSCIENCE RESEARCH (2005)
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice
E Rodriguez-Lebron et al.
MOLECULAR THERAPY (2005)
Altering the tropism of lentiviral vectors through pseudotyping
J Cronin et al.
CURRENT GENE THERAPY (2005)
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model
SQ Harper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
HB Xia et al.
NATURE MEDICINE (2004)
A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration
K Watase et al.
NEURON (2002)
Phosphorothioate oligodeoxynucleotides: What is their origin and what is unique about them?
F Eckstein
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2000)
分享论文
